Pharm Exec4h
FDA Approves Pfizer’s Adcetris for Relapsed or Refractory Large B-Cell Lymphoma
Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
The American Journal of Managed Care8h
TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
kffhealthnews7h
From KFF Health News - Latest Stories:
The Morning Briefing will not be published Monday, Feb. 17, in celebration of Presidents Day. Look for it again in your inbox Tuesday. RFK Jr. Is Sworn In To Lead HHS Amid A Backdrop Of Budget, Staff ...
Pharmabiz16h
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...